Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
...
Health Technology » Pharmaceuticals Other
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| CTLT | Catalent, Inc. | 2.59% | 84.10 | 2.1% | $245.35m | |
| SAVA | Cassava Sciences, Inc. | -2.70% | 11.16 | 0.0% | $215.29m | |
| HZNP | Horizon Therapeutics Plc | 1.82% | 79.67 | 5.8% | $175.38m | |
| JAZZ | Jazz Pharmaceuticals Plc | 1.37% | 141.49 | 2.4% | $172.13m | |
| MRNS | Marinus Pharmaceuticals, Inc. | 0.99% | 11.26 | 7.8% | $129.52m | |
| CORT | Corcept Therapeutics, Inc. | 1.46% | 17.34 | 5.5% | $128.22m | |
| VRX | Valeant Pharmaceuticals International, Inc. | -0.13% | 15.28 | 14.1% | $89.91m | |
| MYOK | MyoKardia, Inc. | 0.89% | 133.90 | 1.8% | $63.32m | |
| BHC | Bausch Health Cos., Inc. | -0.13% | 15.28 | 0.0% | $62.17m | |
| AMRN | Amarin Corp. Plc | 4.99% | 4.00 | 1.5% | $59.91m | |
| ARGX | argenx SE | 2.74% | 255.37 | 0.0% | $55.91m | |
| SAGE | SAGE Therapeutics, Inc. | -1.53% | 59.89 | 8.6% | $45.78m | |
| GWPH | GW Pharmaceuticals Plc | -0.94% | 99.50 | 6.2% | $40.15m | |
| AXSM | Axsome Therapeutics, Inc. | -0.73% | 76.46 | 1.9% | $40.04m | |
| PRGO | Perrigo Co. Plc | 0.80% | 45.60 | 6.8% | $37.20m |
Company Profile
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren on April 25, 2008 and is headquartered in Breda, the Netherlands.